Volume | 509,796 |
|
|||||
News | - | ||||||
Day High | 5.04 | Low High |
|||||
Day Low | 4.61 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Black Diamond Therapeutics Inc | BDTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.03 | 4.61 | 5.04 | 4.74 | 5.04 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,902 | 509,796 | $ 4.78 | $ 2,434,844 | - | 1.62 - 7.66 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:17:03 | 3 | $ 4.84 | USD |
Black Diamond Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
245.14M | 51.72M | - | 0 | -82.44M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Black Diamond Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BDTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.44 | 5.54 | 4.61 | 5.03 | 1,103,243 | -0.70 | -12.87% |
1 Month | 4.97 | 7.66 | 4.61 | 5.85 | 970,720 | -0.23 | -4.63% |
3 Months | 5.22 | 7.66 | 3.72 | 5.43 | 665,943 | -0.48 | -9.20% |
6 Months | 2.31 | 7.66 | 2.155 | 4.59 | 606,806 | 2.43 | 105.19% |
1 Year | 1.86 | 7.66 | 1.62 | 5.25 | 1,505,374 | 2.88 | 154.84% |
3 Years | 13.50 | 14.18 | 1.18 | 5.49 | 690,800 | -8.76 | -64.89% |
5 Years | 33.00 | 46.25 | 1.18 | 9.28 | 576,047 | -28.26 | -85.64% |
Black Diamond Therapeutics Description
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. |